|
1）Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33: 1674-85
|
|
|
|
2）Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997; 336: 633-40
|
|
|
|
|
|
3）Noto H, Tsujimoto T, Noda M. Significantly increased risk of cancer in diabetes mellitus patients: A meta-analysis of epidemiologic evidence in Asians and non-Asians. J Diabetes Invest. 2012; 3: 24-33
|
|
|
|
|
|
4）Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011; 364: 829-41
|
|
|
|
|
|
5）Johnson JA, Bowker SL, Richardson K, et al. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011; 54: 2263-71
|
|
|
|
|
|
6）Bowker SL, Richardson K, Marra CA, et al. Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. Diabetes Care. 2011; 34: 2542-4
|
|
|
|
|
|
7）Noto H, Tsujimoto T, Sasazuki T, et al. Significantly increased risk of cancer in patients with diabetes mellitus. Endocrine Practice. 2011; 17: 616-28
|
|
|
|
|
|
8）Noto H, Osame K, Sasazuki T, et al. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications. 2010; 24: 345-53
|
|
|
|
|
|
9）Renehan A, Smith U, Kirkman MS. Linking diabetes and cancer: a consensus on complexity. Lancet. 2010; 375: 2201-2
|
|
|
|
|
|
10）Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010; 49: 662-71
|
|
|
|
|
|
11）Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010; 3: 1451-61
|
|
|
|
|
|
12）Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010; 46: 2369-80
|
|
|
|
|
|
13）Noto H, Goto A, Tsujimoto T, et al. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012; 7: e33411
|
|
|
|
|
|
14）Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009; 52: 1732-44
|
|
|
|
|
|
15）Jonasson JM, Ljung R, Talback M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009; 52: 1745-54
|
|
|
|
|
|
16）Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009; 52: 1755-65
|
|
|
|
|
|
17）Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766-77
|
|
|
|
|
|
18）McFarland MS, Cripps R. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy. 2010; 30: 1159-78
|
|
|
|
|
|
19）Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia. 2009; 52: 1699-708
|
|
|
|
|
|
20）Hernandez-Diaz S, Adami HO. Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia. 2010; 53: 802-8
|
|
|
|
|
|
21）Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009; 52: 1971-3
|
|
|
|
|
|
22）ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367: 319-28
|
|
|
|
|
|
23）Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010; 59: 1254-60
|
|
|
|
|
|
24）Yang X, So WY, Ma RC, et al. Use of sulphonyl-urea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010; 90: 343-51
|
|
|
|
|
|
25）Chang CH, Lin JW, Wu LC, et al. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97: E1170-5
|
|
|
|
|
|
26）Hsieh MC, Lee TC, Cheng SM, et al. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res. 2012; 2012: 413782
|
|
|
|
|
|
27）Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766-77
|
|
|
|
|
|
28）Monami M, Lamanna C, Balzi D, et al. Sulphonyl-ureas and cancer: a case-control study. Acta Diabetol. 2009; 46: 279-84
|
|
|
|
|
|
29）Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet. 2011; 378: 1543-4; author reply 4-5
|
|
|
|
|
|
30）Piccinni C, Motola D, Marchesini G, et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011; 34: 1369-71
|
|
|
|
|
|
31）Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34: 916-22
|
|
|
|
|
|
32）Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012; 55: 1953-62
|
|
|
|
|
|
33）Actos. Product information as approved by the CHMP on 20 October 2011, pending endorsement by the European Commission (updated 20 December 2011). http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/07/WC500109185.pd
|
|
|
|
|
|
34）Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract. 2012; 98: 159-63
|
|
|
|
|
|
35）Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012; 184: E675-83
|
|
|
|
|
|
36）Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012; 35: 278-80
|
|
|
|
|
|
37）Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012; 35: 278-80
|
|
|
|
|
|
38）Chang CH, Lin JW, Wu LC, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012; 55(5): 1462-72
|
|
|
|
|
|
39）Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastro-enterology. 2011; 141: 150-6
|
|
|
|
|